Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.73
-0.71 (-5.28%)
At close: Apr 7, 2026, 4:00 PM EDT
12.78
+0.04 (0.35%)
After-hours: Apr 7, 2026, 4:17 PM EDT
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
475.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 294.28M |
| 4D Molecular Therapeutics | 85.21M |
| Fulcrum Therapeutics | 80.00M |
| Entrada Therapeutics | 25.42M |
| Shattuck Labs | 1.00M |
| YD Bio | 510.36K |
| Lyell Immunopharma | 36.00K |
| vTv Therapeutics | 17.00K |
CTNM News
- 25 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 5 weeks ago - Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 4 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 4 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
- 4 months ago - Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire